Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2023

Open Access 01-12-2023 | Kidney Cancer | Review

Circular RNAs in renal cell carcinoma: from mechanistic to clinical perspective

Authors: Chunjie Huang, Pooya Esfani Sarafraz, Parisa Enayati, Elham Mortazavi Mamaghani, Emad Babakhanzadeh, Majid Nazari

Published in: Cancer Cell International | Issue 1/2023

Login to get access

Abstract

CircRNAs, a special type of noncoding RNAs characterized by their stable structure and unique abilities to form backsplicing loops, have recently attracted the interest of scientists. These RNAs are abundant throughout the body and play important roles such as microRNA sponges, templates for transcription, and regulation of protein translation and RNA-binding proteins. Renal cancer development is highly correlated with abnormal circRNA expression in vivo. CircRNAs are currently considered promising targets for novel therapeutic approaches as well as possible biomarkers for prognosis and diagnosis of various malignancies. Despite our growing understanding of circRNA, numerous questions remain unanswered. Here, we address the characteristics of circRNAs and their function, focusing in particular on their impact on drug resistance, metabolic processes, metastasis, cell growth, and programmed cell death in renal cancer. In addition, the application of circRNAs as prognostic and diagnostic biomarkers will be discussed.
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.PubMedCrossRef
3.
Elbe N, Sauter G, Epstein J. Pathology and genetics of tumours of the urinary system and male genital organs: international agency for research on cancer (IARC). Oxford: Oxford University Press; 2004.
4.
Singh D. Current updates and future perspectives on the management of renal cell carcinoma. Life Sci. 2021;264:118632.PubMedCrossRef
5.
Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393(10189):2404–15.PubMedCrossRef
6.
Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–15.PubMedPubMedCentralCrossRef
7.
Larroquette M, Peyraud F, Domblides C, Lefort F, Bernhard J-C, Ravaud A, et al. Adjuvant therapy in renal cell carcinoma: current knowledges and future perspectives. Cancer Treat Rev. 2021;97:102207.PubMedCrossRef
8.
Xie Y, Yuan X, Zhou W, Kosiba AA, Shi H, Gu J, et al. The circular RNA HIPK3 (circHIPK3) and its regulation in cancer progression: Review. Life Sci. 2020;254:117252.PubMedCrossRef
9.
Di X, Jin X, Li R, Zhao M, Wang K. CircRNAs and lung cancer: biomarkers and master regulators. Life Sci. 2019;220:177–85.PubMedCrossRef
10.
Sanger HL, Klotz G, Riesner D, Gross HJ, Kleinschmidt AK. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci. 1976;73(11):3852–6.PubMedPubMedCentralCrossRef
11.
Hsu M-T, Coca-Prados M. Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells. Nature. 1979;280:339–40.PubMedCrossRef
12.
van Zonneveld AJ, Kölling M, Bijkerk R, Lorenzen JM. Circular RNAs in kidney disease and cancer. Nat Rev Nephrol. 2021;17(12):814–26.PubMedCrossRef
13.
Wang Y, Zhang Y, Wang P, Fu X, Lin W. Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy. Mol Cancer. 2020;19(1):1–10.CrossRef
14.
15.
Szoka F Jr, Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng. 1980;9(1):467–508.PubMedCrossRef
16.
Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333–8.PubMedCrossRef
17.
Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS ONE. 2012;7(2):e30733.PubMedPubMedCentralCrossRef
18.
Zhang Z-h, Wang Y, Zhang Y, Zheng S-F, Feng T, Tian X, et al. The function and mechanisms of action of circular RNAs in urologic cancer. Mol cancer. 2023;22(1):61.PubMedPubMedCentralCrossRef
19.
20.
Zhang Y, Zhang X-O, Chen T, Xiang J-F, Yin Q-F, Xing Y-H, et al. Circular intronic long noncoding RNAs. Mol Cell. 2013;51(6):792–806.PubMedCrossRef
21.
Itskovich SS, Gurunathan A, Clark J, Burwinkel M, Wunderlich M, Berger MR, et al. MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia. Nat Commun. 2020;11(1):2369.PubMedPubMedCentralCrossRef
22.
Conn SJ, Katherine AP, John Toubia Conn VM, Salmanidis M, Phillips CA, Roslan S, Schreiber AW, Gregory PA, Goodall GJ. The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015;160(6):1125–34.PubMedCrossRef
23.
24.
He AT, Liu J, Li F, Yang BB. Targeting circular RNAs as a therapeutic approach: current strategies and challenges. Signal Transduct Target Ther. 2021;6(1):185.PubMedPubMedCentralCrossRef
25.
Hansen TB, Wiklund ED, Bramsen JB, Villadsen SB, Statham AL, Clark SJ, et al. miRNA-dependent gene silencing involving Ago2-mediated cleavage of a circular antisense RNA. Embo j. 2011;30(21):4414–22.PubMedPubMedCentralCrossRef
26.
Park OH, Ha H, Lee Y, Boo SH, Kwon DH, Song HK, et al. Endoribonucleolytic cleavage of m(6)A-containing RNAs by RNase P/MRP complex. Mol Cell. 2019;74(3):494-507.e8.PubMedCrossRef
27.
Lee Y, Choe J, Park OH, Kim YK. Molecular mechanisms driving mRNA degradation by m(6)A modification. Trends Genet TIG. 2020;36(3):177–88.PubMedCrossRef
28.
Liu CX, Li X, Nan F, Jiang S, Gao X, Guo SK, et al. Structure and degradation of circular RNAs regulate PKR activation in innate immunity. Cell. 2019;177(4):865-80.e21.PubMedCrossRef
29.
30.
Preußer C, Hung LH, Schneider T, Schreiner S, Hardt M, Moebus A, et al. Selective release of circRNAs in platelet-derived extracellular vesicles. J Extracell Vesicles. 2018;7(1):1424473.PubMedPubMedCentralCrossRef
31.
Lasda E, Parker R. Circular RNAs co-precipitate with extracellular vesicles: a possible mechanism for circRNA clearance. PLoS ONE. 2016;11(2):e0148407.PubMedPubMedCentralCrossRef
32.
33.
Memczak S, Papavasileiou P, Peters O, Rajewsky N. Identification and characterization of circular RNAs as a new class of putative biomarkers in human blood. PLoS ONE. 2015;10(10):e0141214.PubMedPubMedCentralCrossRef
34.
van Balkom BW, Pisitkun T, Verhaar MC, Knepper MA. Exosomes and the kidney: prospects for diagnosis and therapy of renal diseases. Kidney Int. 2011;80(11):1138–45.PubMedPubMedCentralCrossRef
35.
36.
Ma X-K, Xue W, Chen L-L, Yang L. CIRCexplorer pipelines for circRNA annotation and quantification from non-polyadenylated RNA-seq datasets. Methods. 2021;196:3–10.PubMedCrossRef
37.
Mi Z, Zhongqiang C, Caiyun J, Yanan L, Jianhua W, Liang L. Circular RNA detection methods: a minireview. Talanta. 2022;238:123066.PubMedCrossRef
38.
D’Ambra E, Morlando M. Study of circular RNA expression by nonradioactive northern blot procedure. In: Navarro A, editor. Long non-coding RNAs in cancer. New York: Springer; 2021. p. 371–83.CrossRef
39.
Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013;19(2):141–57.PubMedPubMedCentralCrossRef
40.
Lin C, Xiao Z, Zhang X, Wu G. In situ hybridization assay for circular RNA visualization based on padlock probe and rolling circle amplification. Biochem Biophys Res Commun. 2022;610:30–4.PubMedCrossRef
41.
Liu Y, Zhang X, Liu M, Xu F, Zhang Q, Zhang Y, et al. Direct detection of circRNA in real samples using reverse transcription-rolling circle amplification. Anal Chim Acta. 2020;1101:169–75.PubMedCrossRef
42.
Jiao J, Gao T, Shi H, Sheng A, Xiang Y, Shu Y, et al. A method to directly assay circRNA in real samples. Chem Commun. 2018;54(95):13451–4.CrossRef
43.
Dahl M, Daugaard I, Andersen MS, Hansen TB, Grønbæk K, Kjems J, et al. Enzyme-free digital counting of endogenous circular RNA molecules in B-cell malignancies. Lab Invest. 2018;98(12):1657–69.PubMedPubMedCentralCrossRef
44.
Tang Q, Chen Z, Zhao L, Xu H. Circular RNA hsa_circ_0000515 acts as a miR-326 sponge to promote cervical cancer progression through up-regulation of ELK1. Aging. 2019;11(22):9982–99.PubMedPubMedCentralCrossRef
45.
Tang W, Fu K, Sun H, Rong D, Wang H, Cao H. CircRNA microarray profiling identifies a novel circulating biomarker for detection of gastric cancer. Mol Cancer. 2018;17(1):1–6.CrossRef
46.
47.
48.
Ma X-K, Wang M-R, Liu C-X, Dong R, Carmichael GG, Chen L-L, et al. CIRCexplorer3: a CLEAR pipeline for direct comparison of circular and linear RNA expression. Genom Proteom Bioinform. 2019;17(5):511–21.CrossRef
49.
Karthik L, Kumar G, Keswani T, Bhattacharyya A, Chandar SS, Bhaskara RK. Protease inhibitors from marine actinobacteria as a potential source for antimalarial compound. PLoS ONE. 2014;9(3):e90972.PubMedPubMedCentralCrossRef
50.
Liu B, Li J, Cairns MJ. Identifying miRNAs, targets and functions. Brief Bioinform. 2014;15(1):1–19.PubMedCrossRef
51.
Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20.PubMedCrossRef
52.
Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384–8.PubMedCrossRef
53.
Kristensen LS, Andersen MS, Stagsted LV, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675–91.PubMedCrossRef
54.
Mao W, Wang K, Xu B, Zhang H, Sun S, Hu Q, et al. ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma. Mol Cancer. 2021;20(1):1–7.
55.
Wang K, Sun Y, Tao W, Fei X, Chang C. Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals. Cancer Lett. 2017;394:1–12.PubMedCrossRef
56.
Liu G, Huang K, Jie Z, Wu Y, Chen J, Chen Z, et al. CircFAT1 sponges miR-375 to promote the expression of Yes-associated protein 1 in osteosarcoma cells. Mol Cancer. 2018;17:1–16.CrossRef
57.
Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015;22(3):256–64.PubMedCrossRef
58.
Ding L, Zhao Y, Dang S, Wang Y, Li X, Yu X, et al. Circular RNA circ-DONSON facilitates gastric cancer growth and invasion via NURF complex dependent activation of transcription factor SOX4. Mol Cancer. 2019;18:1–11.CrossRef
59.
Wang L, Long H, Zheng Q, Bo X, Xiao X, Li B. Circular RNA circRHOT1 promotes hepatocellular carcinoma progression by initiation of NR2F6 expression. Mol Cancer. 2019;18(1):1–12.PubMedPubMedCentralCrossRef
60.
Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;56(1):55–66.PubMedCrossRef
61.
You X, Vlatkovic I, Babic A, Will T, Epstein I, Tushev G, et al. Neural circular RNAs are derived from synaptic genes and regulated by development and plasticity. Nat Neurosci. 2015;18(4):603–10.PubMedPubMedCentralCrossRef
62.
Du WW, Yang W, Liu E, Yang Z, Dhaliwal P, Yang BB. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. Nucleic Acids Res. 2016;44(6):2846–58.PubMedPubMedCentralCrossRef
63.
Zhou B, Yu J-W. A novel identified circular RNA, circRNA_010567, promotes myocardial fibrosis via suppressing miR-141 by targeting TGF-β1. Biochem Biophys Res Commun. 2017;487(4):769–75.PubMedCrossRef
64.
65.
66.
Vickers NJ. Animal communication: when i’m calling you, will you answer too? Curr Biol. 2017;27(14):R713–5.PubMedCrossRef
67.
Zhang M, Huang N, Yang X, Luo J, Yan S, Xiao F, et al. A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis. Oncogene. 2018;37(13):1805–14.PubMedCrossRef
68.
Huang Z, Ding Y, Zhang L, He S, Jia Z, Gu C, et al. Upregulated circPDK1 promotes RCC cell migration and invasion by regulating the miR-377-3P-NOTCH1 Axis in renal cell carcinoma. Onco Targets Ther. 2020;13:11237.PubMedPubMedCentralCrossRef
69.
Luo S, Deng F, Yao N, Zheng F. Circ_0005875 sponges miR-502-5p to promote renal cell carcinoma progression through upregulating E26 transformation specific-1. Anticancer Drugs. 2022;33(1):e286–98.PubMedCrossRef
70.
Gong L-J, Wang XY, Yao X-d, Wu X, Gu W-Y. CircESRP1 inhibits clear cell renal cell carcinoma progression through the CTCF-mediated positive feedback loop. Cell Death Dis. 2021;12(11):1081.PubMedPubMedCentralCrossRef
71.
Gui C-P, Liao B, Luo C-G, Chen Y-H, Tan L, Tang Y-M, et al. circCHST15 is a novel prognostic biomarker that promotes clear cell renal cell carcinoma cell proliferation and metastasis through the miR-125a-5p/EIF4EBP1 axis. Mol Cancer. 2021;20(1):169.PubMedPubMedCentralCrossRef
72.
Cen J, Liang Y, Huang Y, Pan Y, Shu G, Zheng Z, et al. Circular RNA circSDHC serves as a sponge for miR-127-3p to promote the proliferation and metastasis of renal cell carcinoma via the CDKN3/E2F1 axis. Mol Cancer. 2021;20:1–14.CrossRef
73.
Li J, Huang C, Zou Y, Ye J, Yu J, Gui Y. CircTLK1 promotes the proliferation and metastasis of renal cell carcinoma by sponging miR-136-5p. Mol Cancer. 2020;19(1):1–17.PubMedPubMedCentralCrossRef
74.
Li K, Wan C-L, Guo Y. Circular RNA circMTO1 suppresses RCC cancer cell progression via miR9/LMX1A axis. Technol Cancer Res Treat. 2020;19:1533033820914286.PubMedPubMedCentralCrossRef
75.
Sun J, Yin A, Zhang W, Lv J, Liang Y, Li H, et al. CircUBAP2 inhibits proliferation and metastasis of clear cell renal cell carcinoma via targeting miR-148a-3p/FOXK2 pathway. Cell Transplant. 2020;29:0963689720925751.PubMedPubMedCentralCrossRef
76.
Sun J, Pan S, Cui H, Li H. CircRNA SCARB1 promotes renal cell carcinoma progression via miR-510-5p/SDC3 axis. Curr Cancer Drug Targets. 2020;20(6):461–70.PubMedCrossRef
77.
Chen L, Wu D, Ding T. Circular RNA circ_0001368 inhibited growth and invasion in renal cell carcinoma by sponging miR-492 and targeting LATS2. Gene. 2020;753:144781.PubMedCrossRef
78.
Chen Q, Liu T, Bao Y, Zhao T, Wang J, Wang H, et al. CircRNA cRAPGEF5 inhibits the growth and metastasis of renal cell carcinoma via the miR-27a-3p/TXNIP pathway. Cancer Lett. 2020;469:68–77.PubMedCrossRef
79.
Zhang G, Wang J, Tan W, Han X, Han B, Wang H, et al. Circular RNA EGLN3 silencing represses renal cell carcinoma progression through the miR-1224-3p/HMGXB3 axis. Acta Histochem. 2021;123(6):151752.PubMedCrossRef
80.
Zhang D, Yang X-J, Luo Q-D, Fu D-L, Li Z-L, Zhang P, et al. Down-regulation of circular RNA_000926 attenuates renal cell carcinoma progression through miRNA-411–dependent CDH2 inhibition. Am J Pathol. 2019;189(12):2469–86.PubMedCrossRef
81.
Xue D, Wang H, Chen Y, Shen D, Lu J, Wang M, et al. Circ-AKT3 inhibits clear cell renal cell carcinoma metastasis via altering miR-296-3p/E-cadherin signals. Mol Cancer. 2019;18:1–13.CrossRef
82.
Liu Z, Wang R, Zhu G. Circ_0035483 functions as a tumor promoter in renal cell carcinoma via the miR-31–5p-mediated HMGA1 upregulation. Cancer Manag Res. 2021;13:693–706.PubMedPubMedCentralCrossRef
83.
Fang L, Ye T, An Y. Circular RNA FOXP1 induced by ZNF263 upregulates U2AF2 expression to accelerate renal cell carcinoma tumorigenesis and warburg effect through Sponging miR-423–5p. J Immunol Res. 2021;2021:1–16.
84.
Pei L, Lv X, Jia G, Tan X, Li M, Zhang A. Silencing circular RNA circ_0054537 and upregulating microRNA-640 suppress malignant progression of renal cell carcinoma via regulating neuronal pentraxin-2 (NPTX2). Bioengineered. 2021;12(1):8279–95.PubMedPubMedCentralCrossRef
85.
Yang L, Wang L, Wu J, Wang Y. Circ_0000069 contributes to the growth, metastasis and glutamine metabolism in renal cell carcinoma (RCC) via regulating miR-125a-5p-dependent SLC1A5 expression. Transpl Immunol. 2023;77:101764.PubMedCrossRef
86.
Wang Y, Zhang Y, Su X, Qiu Q, Yuan Y, Weng C, et al. Circular RNA circDVL1 inhibits clear cell renal cell carcinoma progression through the miR-412-3p/PCDH7 axis. Int J Biol Sci. 2022;18(4):1491.PubMedPubMedCentralCrossRef
87.
88.
Xie X, Li H, Gao C, Lai Y, Liang J, Chen Z, et al. Downregulation of Circular RNA circPSD3 promotes metastasis by modulating FBXW7 expression in clear cell renal cell carcinoma. Journal of Oncology. 2022;2022:1–18.
89.
Li J, Huang C, Zou Y, Yu J, Gui Y. Circular RNA MYLK promotes tumour growth and metastasis via modulating miR-513a-5p/VEGFC signalling in renal cell carcinoma. J Cell Mol Med. 2020;24(12):6609–21.PubMedPubMedCentralCrossRef
90.
Yang C-Y, Wang J, Zhang J-Q, Cai H-m. Human circular RNA hsa_circRNA_101705 (circTXNDC11) regulates renal cancer progression by regulating MAPK/ERK pathway. Bioengineered. 2021;12(1):4432–41.PubMedPubMedCentralCrossRef
91.
Li R, Luo S, Zhang D. Circular RNA hsa_circ_0054537 sponges miR-130a-3p to promote the progression of renal cell carcinoma through regulating cMet pathway. Gene. 2020;754:144811.PubMedCrossRef
92.
Lin L, Cai J. Circular RNA circ-EGLN3 promotes renal cell carcinoma proliferation and aggressiveness via miR-1299-mediated IRF7 activation. J Cell Biochem. 2020;121(11):4377–85.PubMedCrossRef
93.
Zeng J, Feng Q, Wang Y, Xie G, Li Y, Yang Y, et al. Circular RNA circ_001842 plays an oncogenic role in renal cell carcinoma by disrupting microRNA-502-5p-mediated inhibition of SLC39A14. J Cell Mol Med. 2020;24(17):9712–25.PubMedPubMedCentralCrossRef
94.
Yu R, Yao J, Ren Y. A novel circRNA, circNUP98, a potential biomarker, acted as an oncogene via the miR-567/PRDX3 axis in renal cell carcinoma. J Cell Mol Med. 2020;24(17):10177–88.PubMedPubMedCentralCrossRef
95.
Wang G, Xue W, Jian W, Liu P, Wang Z, Wang C, et al. The effect of Hsa_circ_0001451 in clear cell renal cell carcinoma cells and its relationship with clinicopathological features. J Cancer. 2018;9(18):3269.PubMedPubMedCentralCrossRef
96.
Han B, Shaolong E, Luan L, Li N, Liu X. CircHIPK3 promotes clear cell renal cell carcinoma (ccRCC) cells proliferation and metastasis via altering of miR-508-3p/CXCL13 signal. Onco Targets Ther. 2020;13:6051.PubMedPubMedCentralCrossRef
97.
Franz A, Ralla B, Weickmann S, Jung M, Rochow H, Stephan C, et al. Circular RNAs in clear cell renal cell carcinoma: their microarray-based identification, analytical validation, and potential use in a clinico-genomic model to improve prognostic accuracy. Cancers. 2019;11(10):1473.PubMedPubMedCentralCrossRef
98.
Rashedi S, Mardani M, Rafati A, Khavandi MM, Mohammadi F, Javanshir S, et al. Circular RNAs as prognostic and diagnostic biomarkers in renal cell carcinoma. J Clin Lab Anal. 2022;36(10):e24670.PubMedPubMedCentralCrossRef
99.
Li W, Yang F-Q, Sun C-M, Huang J-H, Zhang H-M, Li X, et al. circPRRC2A promotes angiogenesis and metastasis through epithelial-mesenchymal transition and upregulates TRPM3 in renal cell carcinoma. Theranostics. 2020;10(10):4395.PubMedPubMedCentralCrossRef
100.
Liu G, Zhou J, Piao Y, Zhao X, Zuo Y, Ji Z. Hsa_circ_0085576 promotes clear cell renal cell carcinoma tumorigenesis and metastasis through the miR-498/YAP1 axis. Aging. 2020;12(12):11530.PubMedPubMedCentralCrossRef
101.
Frey L, Klümper N, Schmidt D, Kristiansen G, Toma M, Ritter M, et al. CircEHD2, CircNETO2 and CircEGLN3 as diagnostic and prognostic biomarkers for patients with renal cell carcinoma. Cancers. 2021;13(9):2177.PubMedPubMedCentralCrossRef
102.
Huang Y, Zhang Y, Jia L, Liu C, Xu F. Circular RNA ABCB10 promotes tumor progression and correlates with pejorative prognosis in clear cell renal cell carcinoma. Int J Biol Markers. 2019;34(2):176–83.PubMedCrossRef
103.
He T, Zhang Q, Xu P, Tao W, Lin F, Liu R, et al. Extracellular vesicle-circEHD2 promotes the progression of renal cell carcinoma by activating cancer-associated fibroblasts. Mol Cancer. 2023;22(1):117.PubMedPubMedCentralCrossRef
104.
Herculano-Houzel S. The human brain in numbers: a linearly scaled-up primate brain. Front Human Neurosci. 2009;3:31.CrossRef
105.
Osenberg S, Paz Yaacov N, Safran M, Moshkovitz S, Shtrichman R, Sherf O, et al. Alu sequences in undifferentiated human embryonic stem cells display high levels of A-to-I RNA editing. PLoS ONE. 2010;5(6):e11173.PubMedPubMedCentralCrossRef
106.
Di Timoteo G, Rossi F, Bozzoni I. Circular RNAs in cell differentiation and development. Development. 2020;147(16):dev182725.PubMedCrossRef
107.
108.
Huang K-B, Pan Y-H, Shu G-N, Yao H-H, Liu X, Zhou M, et al. Circular RNA circSNX6 promotes sunitinib resistance in renal cell carcinoma through the miR-1184/GPCPD1/lysophosphatidic acid axis. Cancer Lett. 2021;523:121–34.PubMedCrossRef
109.
Zhang M-x, Wang J-l, Mo C-q, Mao X-p, Feng Z-h, Li J-y, et al. CircME1 promotes aerobic glycolysis and sunitinib resistance of clear cell renal cell carcinoma through cis-regulation of ME1. Oncogene. 2022;41(33):3979–90.PubMedPubMedCentralCrossRef
110.
Yan L, Liu G, Cao H, Zhang H, Shao F. Hsa_circ_0035483 sponges hsa-miR-335 to promote the gemcitabine-resistance of human renal cancer cells by autophagy regulation. Biochem Biophys Res Commun. 2019;519(1):172–8.PubMedCrossRef
111.
Harries LW, Hernandez D, Henley W, Wood AR, Holly AC, Bradley-Smith RM, et al. Human aging is characterized by focused changes in gene expression and deregulation of alternative splicing. Aging Cell. 2011;10(5):868–78.PubMedCrossRef
112.
Schneider T, Schreiner S, Preußer C, Bindereif A, Rossbach O. Northern blot analysis of circular RNAs. Circular RNAs: Methods Protoc. 2018;1724:119–33.CrossRef
113.
Zhou T, Xie X, Li M, Shi J, Zhou JJ, Knox KS, et al. Rat BodyMap transcriptomes reveal unique circular RNA features across tissue types and developmental stages. RNA. 2018;24(11):1443–56.PubMedPubMedCentralCrossRef
114.
115.
Du WW, Yang W, Li X, Awan FM, Yang Z, Fang L, et al. A circular RNA circ-DNMT1 enhances breast cancer progression by activating autophagy. Oncogene. 2018;37(44):5829–42.PubMedCrossRef
116.
Fang L, Du WW, Awan FM, Dong J, Yang BB. The circular RNA circ-Ccnb1 dissociates Ccnb1/Cdk1 complex suppressing cell invasion and tumorigenesis. Cancer Lett. 2019;459:216–26.PubMedCrossRef
117.
Schultz N, Marenstein DR, De Angelis DA, Wang W-Q, Nelander S, Jacobsen A, et al. Off-target effects dominate a large-scale RNAi screen for modulators of the TGF-β pathway and reveal microRNA regulation of TGFBR2. Silence. 2011;2(1):1–20.CrossRef
118.
Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L, et al. Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA. 2006;12(7):1179–87.PubMedPubMedCentralCrossRef
119.
Setten RL, Rossi JJ, Han S-p. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421–46.PubMedCrossRef
120.
Dancy JG, Wadajkar AS, Connolly NP, Galisteo R, Ames HM, Peng S, et al. Decreased nonspecific adhesivity, receptor-targeted therapeutic nanoparticles for primary and metastatic breast cancer. Sci Adv. 2020;6(3):eaax3931.PubMedPubMedCentralCrossRef
121.
Jia Y-P, Ma B-Y, Wei X-W, Qian Z-Y. The in vitro and in vivo toxicity of gold nanoparticles. Chin Chem Lett. 2017;28(4):691–702.CrossRef
Metadata
Title
Circular RNAs in renal cell carcinoma: from mechanistic to clinical perspective
Authors
Chunjie Huang
Pooya Esfani Sarafraz
Parisa Enayati
Elham Mortazavi Mamaghani
Emad Babakhanzadeh
Majid Nazari
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2023
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-023-03128-w

Other articles of this Issue 1/2023

Cancer Cell International 1/2023 Go to the issue

Research

Macrophage’s role in solid tumors: two edges of a sword

Review

Epigenetic and metabolic reprogramming in inflammatory bowel diseases: diagnostic and prognostic biomarkers in colorectal cancer

Research

Downregulation of MAL2 inhibits breast cancer progression through regulating β-catenin/c-Myc axis

Research

In vitro co-culture systems of hepatic and intestinal cells for cellular pharmacokinetic and pharmacodynamic studies of capecitabine against colorectal cancer

Research

In vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation

Research

Novel risk model based on angiogenesis-related lncRNAs for prognosis prediction of hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits